Skip to main
VALN
VALN logo

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE reported a 13% year-over-year increase in product sales, rising from €144.6 million in 2023 to €163.3 million in 2024, contributing to a total revenue of €169.6 million for the same period, which reflects a 10% increase from €153.7 million in the previous year. The company has achieved accelerated FDA approval for its vaccine Ixchiq, targeting chikungunya, and projects sales of this vaccine to reach €3 million in 2024, with growth expectations to €250 million by 2029. Valneva anticipates that Ixchiq will generate significant revenue, estimating sales exceeding €100 million by the third year post-launch, in line with expectations for the overall chikungunya vaccine market to surpass $500 million annually.

Bears say

Valneva SE is adjusting its financial projections negatively, with a revised 2025 revenue estimate decreased to €185.0 million from €222.5 million, highlighting a significant reduction in expected cash flows. Additionally, the company's operating cash burn is set to be substantially lowered to less than $30 million in 2025, a stark contrast to over €60 million in 2024, indicating tight financial management challenges. This financial tightening is further emphasized by the downward adjustment of the 2025 EPS estimate to (€0.65) from (€0.53), reflecting deteriorating profitability expectations and reduced sales forecasts for key products like Ixchiq.

Valneva SE (VALN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.